Siedem kroków sitagliptyny – drogowskaz terapeutyczny dla lekarza praktyka Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2025
Słowa kluczowe:
inhibitory dipeptydylopeptydazy 4, sitagliptyna, cukrzyca typu 2
##plugins.themes.bootstrap3.article.main##
Abstrakt
Sitagliptyna jest najczęściej stosowanym przedstawicielem inhibitorów dipeptydylopeptydazy 4 (DPP-4), zwanych gliptynami. Według aktualnych zaleceń Polskiego Towarzystwa Diabetologicznego inhibitory DPP-4 stanowią element terapii cukrzycy typu 2 na etapie rozpoczęcia monoterapii, w przypadku nietolerancji metforminy lub na etapie intensyfikacji terapii w dążeniu do osiągnięcia celu glikemicznego przy jednoczesnej edukacji pacjenta i postępowaniu behawioralnym. Dzięki dobrej tolerancji, brakowi istotnych działań niepożądanych i bezpiecznemu profilowi sercowo-naczyniowemu sitagliptyna może być łączona z innymi grupami leków przeciwhiperglikemicznych, w tym z insuliną, również u chorych z przewlekłą chorobą nerek. Drogowskaz terapeutyczny wyznacza możliwe kierunki zastosowania sitagliptyny w praktyce lekarskiej.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Łebkowska, A. (2025). Siedem kroków sitagliptyny – drogowskaz terapeutyczny dla lekarza praktyka . Medycyna Faktów , 18(1(66), 85-90. https://doi.org/10.24292/01.MF.0125.13
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Araszkiewicz A, Borys S, Broncel M et al. Zalecenia kliniczne dotyczące postępowania u osób z cukrzycą – 2025. Stanowisko Polskiego Towarzystwa Diabetologicznego. Curr Top Diabetes. 2025; 5: 1-163.
2. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4): 773-95.
3. Green JB, Bethel MA, Armstrong PW et al.; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015; 373(3): 232-42.
4. Scott LJ. Sitagliptin: A Review in Type 2 Diabetes. Drugs. 2017; 77(2): 209-24.
5. Enzan N, Matsushima S, Kaku H et al. Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes. JACC Asia. 2023; 3(1): 93-104.
6. Yanagimachi T, Fujita Y, Takeda Y et al. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects. Mol Metab. 2016; 6(2): 226-31.
7. Zaccardi F, Jacquot E, Cortese V et al. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2020; 22(12): 2417-26.
8. Zhang Y, Hong J, Chi J et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev. 2014; 30(3): 241-56.
9. Sakura H, Hashimoto N, Sasamoto K et al. Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study. BMC Endocr Disord. 2016; 16(1): 70.
10. Chen R, Li J, Chen D et al. Efficacy and Safety of DPP-4 Inhibitors and Metformin Combinations in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis. Diabetes Metab Syndr Obes. 2024; 17: 2471-93.
11. Frias JP, Zimmer Z, Lam RLH et al. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study. Diabetes Obes Metab. 2019; 21(5): 1128-35.
12. Roussel M, Mathieu J, Dalle S. Molecular mechanisms redirecting the GLP-1 receptor signalling profile in pancreatic β-cells during type 2 diabetes. Horm Mol Biol Clin Investig. 2016; 26(2): 87-95.
13. Derosa G, Carbone A, Franzetti I et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract. 2012; 98(1): 51-60.
14. Matthews DR, Paldánius PM, Proot P et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019; 394(10208): 1519-29.
15. Tsapas A, Karagiannis T, Kakotrichi P et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Obes Metab. 2021; 23(9): 2116-24.
16. Zhang Y, Hong J, Chi J et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas – a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev. 2014; 30(3): 241-56.
17. Tanase DM, Gosav EM, Costea CF et al. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res. 2020; 2020: 3920196.
18. Jang H, Kim Y, Lee DH et al. Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease. JAMA Intern Med. 2024; 184(4): 375-83.
19. Charakterystyka produktu leczniczego Jazeta.
20. Li M, Wang S, Wang X. Efficacy and Safety of Triple Therapy with SGLT-2 Inhibitor, DPP-4 Inhibitor, and Metformin in Type 2 Diabetes: A Meta-Analysis. Altern Ther Health Med. 2023; 29(5): 320-6.
21. Shankar RR, Bao Y, Han P et al. Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes. J Diabetes Investig. 2017; 8(3): 321-9.
22. de Boer IH, Khunti K, Sadusky T et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022; 45(12): 3075-90.
23. Kawanami D, Takashi Y, Takahashi H et al. Renoprotective Effects of DPP-4 Inhibitors. Antioxidants (Basel). 2021; 10(2): 246.
2. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4): 773-95.
3. Green JB, Bethel MA, Armstrong PW et al.; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015; 373(3): 232-42.
4. Scott LJ. Sitagliptin: A Review in Type 2 Diabetes. Drugs. 2017; 77(2): 209-24.
5. Enzan N, Matsushima S, Kaku H et al. Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes. JACC Asia. 2023; 3(1): 93-104.
6. Yanagimachi T, Fujita Y, Takeda Y et al. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects. Mol Metab. 2016; 6(2): 226-31.
7. Zaccardi F, Jacquot E, Cortese V et al. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2020; 22(12): 2417-26.
8. Zhang Y, Hong J, Chi J et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev. 2014; 30(3): 241-56.
9. Sakura H, Hashimoto N, Sasamoto K et al. Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study. BMC Endocr Disord. 2016; 16(1): 70.
10. Chen R, Li J, Chen D et al. Efficacy and Safety of DPP-4 Inhibitors and Metformin Combinations in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis. Diabetes Metab Syndr Obes. 2024; 17: 2471-93.
11. Frias JP, Zimmer Z, Lam RLH et al. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study. Diabetes Obes Metab. 2019; 21(5): 1128-35.
12. Roussel M, Mathieu J, Dalle S. Molecular mechanisms redirecting the GLP-1 receptor signalling profile in pancreatic β-cells during type 2 diabetes. Horm Mol Biol Clin Investig. 2016; 26(2): 87-95.
13. Derosa G, Carbone A, Franzetti I et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract. 2012; 98(1): 51-60.
14. Matthews DR, Paldánius PM, Proot P et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019; 394(10208): 1519-29.
15. Tsapas A, Karagiannis T, Kakotrichi P et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Obes Metab. 2021; 23(9): 2116-24.
16. Zhang Y, Hong J, Chi J et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas – a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev. 2014; 30(3): 241-56.
17. Tanase DM, Gosav EM, Costea CF et al. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res. 2020; 2020: 3920196.
18. Jang H, Kim Y, Lee DH et al. Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease. JAMA Intern Med. 2024; 184(4): 375-83.
19. Charakterystyka produktu leczniczego Jazeta.
20. Li M, Wang S, Wang X. Efficacy and Safety of Triple Therapy with SGLT-2 Inhibitor, DPP-4 Inhibitor, and Metformin in Type 2 Diabetes: A Meta-Analysis. Altern Ther Health Med. 2023; 29(5): 320-6.
21. Shankar RR, Bao Y, Han P et al. Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes. J Diabetes Investig. 2017; 8(3): 321-9.
22. de Boer IH, Khunti K, Sadusky T et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022; 45(12): 3075-90.
23. Kawanami D, Takashi Y, Takahashi H et al. Renoprotective Effects of DPP-4 Inhibitors. Antioxidants (Basel). 2021; 10(2): 246.